Is Earlier Treatment Better For Patients? The Case of Docetaxel in Metastatic Castration-Sensiti...

Modern Treatment Approaches to Prostate CancerПодробнее

Is There Still a Role for Docetaxel in mHSPC?Подробнее

Treatment intensification in metastatic castration-sensitive prostate cancerПодробнее

Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate CancerПодробнее

Dr. Higano on Docetaxel for Hormone-Sensitive Prostate CancerПодробнее

Prostate Cancer: Clinical Guidelines, Novel Therapies, and Therapeutic UncertaintyПодробнее

Ask the Expert: Do Low Volume Metastatic Disease Patients Benefit from Early Docetaxal?Подробнее

Abiraterone vs docetaxel for metastatic castrate resistant prostate cancerПодробнее

Timing of ADT and ChemotherapyПодробнее

Emerging management of metastatic castration-sensitive prostate cancer: front-line chemotherapy ...Подробнее

ProCAID: capivasertib plus docetaxel and prednisolone chemotherapy for the treatment of mCRPCПодробнее

ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancerПодробнее

Role of the addition of docetaxel to ADT in mHSPCПодробнее

Docetaxel in Non-metastatic Prostate CancerПодробнее

Dr. Burgess on Key Data in Metastatic Castration-Sensitive Prostate CancerПодробнее

Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based DiscussionПодробнее

Docetaxel in Metastatic Prostate CancerПодробнее

Is there still a role for docetaxel in mHSPC?Подробнее

Dr. Oh Discusses the Use of Abiraterone and Docetaxel in Prostate CancerПодробнее

BMI and clinical outcomes in patients with metastatic castration-resistant prostate cancerПодробнее

Dr. Patel on Early Treatment With Docetaxel for Metastatic Prostate CancerПодробнее

Case Study 1: Hormone-sensitive, metastatic CRPCПодробнее